篇名

從用藥風險分擔論藥害救濟制度之救濟限制──以藥害救濟法第13條第9款為中心   免費試閱

並列篇名

Clarifying the Scope of Drug Injury Relief System from the Perspective of Risk Allocation in Drug Usage: Focus on Article 13, Subparagraph 9 of the Drug Injury Relief Act

中文摘要

臺灣藥害救濟制度係指正當使用合法藥物發生嚴重藥物不良反應致死亡、障礙或嚴重疾病之情形,在符合藥害救濟法下所列之要件且無同法第13條規定之排除情形者,可獲得金錢補償的制度。有關藥害救濟法第13條第9款常見且可預期藥物不良反應不予救濟之規定,在司法院釋字第767號解釋後,引起社會輿論媒體不小的討論,討論的核心主要圍繞在系爭規定是否符合法律明確性及比例原則等議題。本文試著從「用藥風險分擔」的角度剖析臺灣藥害救濟制度的救濟限制,特別是排除常見且可預期之藥物不良反應之理由,以提供各界另一個面向的思考。

英文摘要

Taiwan drug injury relief system provides timely relief for drug injuries resulting in serious illness, disability or death, despite the proper use of legal drugs. Victims or their families may request for the relief according to the Drug Injury Relief Act (Act), provided that all of the requirements stipulated under the Act are met and no conditions prescribed in Article 13 of Act are noted. The Constitutional Court under the Judicial Yuan (J.Y.) issued J.Y. Interpretation No. 767 and declared that Article 13(9) of Act (i.e., the common and foreseeable adverse reaction from drug usage is not eligible for the drug injury relief) contradicted neither to the principle of clarity and definiteness of law nor to the proportionality principle in July, 2018. Since then, widespread criticism has been risen from Taiwanese society. Different from most of the published articles, in relation to the J.Y. Interpretation No. 767 or Article 13(9) of Act, focus on the principle of clarity and definiteness of law, this article tries to clarify the scope of drug injury relief system, especially the rationale behind Article 13(9) of Act, from the perspective of risk allocation in drug usage.

起訖頁

146-164

出版單位
DOI

10.3966/241553062020100048011  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP